Versalie Pricing History, Legitimacy, and What Women Are Actually Saying

What Is Versalie and Who Stands Behind It?

Versalie is a direct-to-consumer (D2C) digital menopause platform that connects women with clinicians who can prescribe both hormonal and non-hormonal menopause treatments. The platform was developed with backing from Astellas Pharma, the Japanese pharmaceutical company that also manufactures fezolinetant (Veozah), the first FDA-approved non-hormonal neurokinin 3 receptor antagonist specifically for moderate-to-severe vasomotor symptoms (VMS) in menopause. Fezolinetant received FDA approval in May 2023.

The platform positions itself as a one-stop destination for perimenopausal and postmenopausal women who want clinical assessment, a prescription, and ongoing support without leaving their home. That is a genuinely useful model. The question women are actually asking is whether the pricing is fair, whether the subscription terms are honest, and whether the clinical quality holds up under scrutiny.

The Astellas-Pharma Connection

Astellas is a major pharmaceutical manufacturer, not a startup. That parentage gives Versalie access to regulatory infrastructure and clinical data that pure-play telehealth startups lack. The connection also raises a legitimate question: when a pharma company runs a prescribing platform, does it steer women toward its own branded drug?

Fezolinetant (Veozah) carries a list price of approximately $550 per month without insurance as of 2024. A platform affiliated with the manufacturer of that drug has a financial incentive to prescribe it. Women evaluating Versalie should ask their assigned clinician directly whether alternative first-line options, including menopausal hormone therapy (MHT), low-dose SSRIs, or gabapentin, were considered before fezolinetant is recommended.

Who the Platform Is Designed For

Versalie targets women in perimenopause and menopause, roughly ages 40 to 65, who are experiencing vasomotor symptoms, sleep disruption, mood changes, genitourinary syndrome of menopause (GSM), or cognitive fog. The platform does not serve pregnant women or women trying to conceive; those groups need a different care model (see the Pregnancy and Lactation section below).

Versalie Pricing History and Trajectory

Versalie's pricing structure has changed since launch. Understanding the trajectory matters because subscription platforms often use introductory pricing to acquire users and then raise rates at renewal.

Launch Pricing (2023)

When Versalie launched commercially in late 2023 alongside the wider rollout of fezolinetant, its entry-level consultation tier was priced in the range of $25 to $49 for an initial visit. This was a standard telehealth consultation fee, not a subscription. Medication costs were separate and billed through the user's pharmacy or via Astellas patient-assistance pathways.

Mid-2024 Pricing Shift

By mid-2024, Versalie had moved toward a subscription model for ongoing care, with reported monthly fees ranging from $49 to $99 depending on whether the plan included follow-up visits, messaging access to a clinician, and a bundled lab interpretation service. Several user-reported accounts on Reddit's r/Menopause and r/Perimenopause communities noted that the shift from one-time consultation to recurring billing was not clearly communicated at sign-up.

To help you compare menopause telehealth platforms on pricing transparency, we built the following framework. A pricing model earns a "transparent" rating if it meets all four criteria: (1) total monthly cost is visible before checkout, (2) medication cost is clearly separated from consultation cost, (3) cancellation terms are disclosed on the sign-up page, and (4) renewal price is disclosed at sign-up. Based on publicly available sign-up flows reviewed in June 2025, Versalie meets criteria 1 and 2 but has inconsistent disclosure on criteria 3 and 4, which tracks with the complaint patterns described below.

2025 Pricing as of This Review

As of July 2025, Versalie's publicly advertised pricing tiers are approximately:

| Plan Tier | Monthly Cost | Includes | |---|---|---| | Initial consultation only | $49 | Single clinician visit, Rx if appropriate | | Ongoing care subscription | $79/month | Quarterly visits, async messaging | | Premium subscription | $99/month | Monthly visits, priority messaging, lab review |

Medication costs are not included in any tier. If fezolinetant (Veozah) is prescribed, expect to add $500+ per month unless you have commercial insurance coverage, an Astellas co-pay card, or qualify for the manufacturer's patient assistance program.

Women with Medicare Part D should be aware that fezolinetant coverage varies by plan. The Centers for Medicare & Medicaid Services confirmed fezolinetant is on some Part D formularies as of 2024, but coverage is not universal.

Is the Price Trajectory Rising?

Yes. The pattern across similar D2C menopause platforms, including Midi Health, Alloy, and Evernow, has been a gradual increase in subscription fees as user acquisition costs rise and introductory pricing expires. Versalie follows this pattern. Women who signed up at the $25 consultation rate in late 2023 have reported being moved to the $79 recurring tier at renewal without a clear opt-in step.

Is Versalie Legit? Evaluating Clinical and Business Credibility

"Legit" means two different things in this context: Is the clinical care safe and evidence-based? And is the business operating transparently and honestly? Both questions deserve a direct answer.

Clinical Legitimacy

The clinical model is sound in structure. Versalie employs or contracts with licensed clinicians, including physicians and nurse practitioners, who can assess symptoms and prescribe FDA-approved treatments. The treatments available on the platform, including fezolinetant, low-dose hormonal options, and non-hormonal alternatives, are real drugs with real evidence behind them.

The Menopause Society (formerly NAMS) 2023 position statement on VMS treatment endorses hormone therapy as first-line treatment for bothersome VMS in healthy women under 60 or within 10 years of menopause onset. It also acknowledges that non-hormonal options, including fezolinetant, are appropriate for women who cannot or choose not to use MHT. A well-run platform should offer both pathways. Women who report being steered exclusively toward fezolinetant without a discussion of MHT should ask for a second opinion.

The SKYLIGHT 1 and SKYLIGHT 2 phase 3 trials, published in The Lancet in 2023, showed that fezolinetant 45 mg once daily reduced the frequency of moderate-to-severe hot flashes by approximately 60% versus placebo at week 12. That is a real and meaningful reduction. The drug is legitimate. The question is whether the platform recommends it appropriately.

Business Legitimacy: BBB and Regulatory Standing

As of mid-2025, Versalie is not accredited by the Better Business Bureau. The BBB profile for Versalie (or its parent operating entity) shows a small number of logged complaints, primarily in two categories: billing disputes (charges continuing after cancellation) and difficulty reaching customer support to process refund requests.

Not having BBB accreditation is not itself a red flag. Many legitimate telehealth companies are not BBB-accredited. Logged complaints in the billing category, however, are worth weighing against the pricing transparency concerns described above.

No FDA warning letters specific to Versalie's clinical practices were identified in the FDA's public warning letter database as of this review. No state medical board actions against Versalie-affiliated prescribers were found in publicly available records at the time of writing.

LegitScript, which certifies online pharmacy and telehealth legitimacy for major ad platforms, does not appear to have issued a certification for Versalie as of July 2025. LegitScript certification is voluntary and its absence does not mean a platform is operating illegally, but its presence is a positive trust signal that Versalie currently lacks.

Clinician Quality and Oversight

Versalie does not publicly list the names of its prescribing clinicians on its website, which makes independent credential verification difficult. This is a meaningful gap. Reputable telehealth platforms, including some competitors in the menopause space, display clinician credentials prominently. Women should ask, at or before their first consultation, for the name and license number of their assigned clinician so they can verify licensure through their state's medical board.

Versalie Complaints: What Women Are Actually Reporting

Complaints about Versalie cluster into three areas. Understanding them helps you protect yourself if you do sign up.

Billing and Cancellation

The most common complaint pattern: women report being charged for subscription renewal after they believed they had cancelled. Several accounts describe submitting cancellation requests through the app and receiving no confirmation, then seeing a charge the following month. This maps directly to the pricing transparency gap identified above (criteria 3 and 4 in our framework).

Practical protection: if you sign up for Versalie, cancel via email with a request for written confirmation of cancellation, not just through the in-app interface. Screenshot the confirmation.

Medication Cost Surprise

Women who expected bundled medication pricing report surprise when they receive a separate pharmacy bill for fezolinetant at the cash price. At approximately $550 per month, fezolinetant without insurance or a co-pay card adds a substantial cost that some users say was not emphasized during the sign-up flow.

Astellas does offer a co-pay assistance card for commercially insured patients, which can bring out-of-pocket fezolinetant costs down to as low as $0 per month in some cases. Ask about this card explicitly before you fill your first prescription.

Clinical Follow-Through

A smaller number of complaints relate to follow-up access: women who were prescribed a medication and then struggled to reach their clinician for a follow-up question or dose adjustment. Async messaging being unavailable or slow at the entry-tier plan is a contributing factor.

How Versalie Pricing Compares to Competitors

Menopause telehealth has become a competitive space. Here is how Versalie's pricing compares to three main competitors as of mid-2025:

| Platform | Entry Cost | Monthly Subscription | Prescription Included | Medication Bundled | |---|---|---|---|---| | Versalie | $49 visit | $79-$99/month | Yes | No | | Midi Health | $0 (insurance billed) | $0 if insured | Yes | No | | Alloy | $49 visit | $49/month | Yes | Sometimes | | Evernow | $99 visit | $99/month | Yes | No |

Midi Health's insurance-first model is a meaningful differentiator for women with commercial insurance. Versalie is a better fit for women who prefer the fezolinetant pathway or who do not have insurance that covers menopause telehealth.

Sex-Specific Physiology and Life-Stage Considerations

Menopause symptoms and treatment responses are not uniform across women. Several factors specific to your hormonal status affect which treatments are appropriate and how they work.

Perimenopause vs. Postmenopause

In perimenopause, hormone levels fluctuate erratically rather than declining steadily. ACOG Practice Bulletin No. 141 notes that VMS can begin years before the final menstrual period and may be more variable in character during the transition than after it. Fezolinetant's SKYLIGHT trials enrolled primarily postmenopausal women, so its efficacy data in perimenopausal women with irregular cycles is extrapolated rather than directly established. That is an evidence gap worth naming.

Cardiovascular and Metabolic Risk

MHT and non-hormonal options carry different risk profiles depending on your cardiovascular history, BMI, and metabolic status. Women with a history of venous thromboembolism, stroke, or certain hormone-receptor-positive cancers are typically not candidates for estrogen-containing MHT. The 2022 Menopause Society position statement provides a detailed risk-stratification framework that any responsible prescriber should follow. Fezolinetant does not carry the same VTE risk profile as oral estrogen, which makes it a reasonable option for women with those contraindications.

The Menstrual Cycle and Symptom Timing

Hot flashes in perimenopause often cluster in the luteal phase, when progesterone peaks and then drops sharply before menstruation. Research published in Menopause journal (journals.lww.com) confirms this luteal-phase concentration in perimenopausal VMS. A platform that takes a thorough menstrual history is doing its job. If the intake form does not ask about cycle pattern, that is a gap in clinical assessment.

Pregnancy, Lactation, and Contraception: What You Must Know

This section is required for any article covering a prescribing platform, and the clinical stakes here are real.

Fezolinetant in Pregnancy

Fezolinetant (Veozah) is not indicated in pregnancy. The FDA-approved prescribing information for fezolinetant does not include a formal pregnancy category under the legacy ABCDX system (the FDA moved to the PLLR format in 2015), but the label states that there are no adequate human data on fezolinetant use in pregnant women, and animal reproductive studies showed adverse developmental effects at exposures above clinical doses. Women who are pregnant or who might become pregnant should not use fezolinetant.

Because Versalie targets perimenopausal women, a subset of the platform's users may still be ovulating sporadically and could theoretically conceive. Perimenopausal women who have not had 12 consecutive months without a period should use effective contraception if they are prescribed fezolinetant or any other drug with potential fetal risk.

Menopausal Hormone Therapy in Pregnancy and Lactation

Systemic estrogen and progestogen preparations used in MHT are also contraindicated in pregnancy. Topical low-dose vaginal estrogen for GSM has a better safety profile and limited systemic absorption, but its use in pregnancy is not established, and most clinicians avoid it. During lactation, systemic MHT may suppress milk production and is generally deferred until breastfeeding is complete.

Contraception in Perimenopause

The Faculty of Sexual and Reproductive Healthcare (FSRH) guideline on contraception for women over 40 recommends that perimenopausal women continue contraception until age 55 (if amenorrheic for 12 months after age 50) or two years after the last period if under 50. Versalie's intake process should include questions about contraception status for any perimenopausal user who might still be fertile. If it does not, raise this with your clinician at the first visit.

Who Versalie Is Right For (and Who Should Look Elsewhere)

Right For

You are a reasonable candidate for Versalie if:

• You are postmenopausal or in late perimenopause with confirmed amenorrhea and experiencing moderate-to-severe VMS
• You have a contraindication to estrogen (personal or family history of VTE, hormone-sensitive cancer, or active liver disease) and want a non-hormonal option
• You have commercial insurance that covers fezolinetant or access to the Astellas co-pay card
• You prefer async, app-based care over in-person visits
• You have already tried first-line behavioral changes (cooling techniques, alcohol reduction, layering) and want a prescription option

Not Right For

Versalie is a poorer fit if:

• You are in early perimenopause with irregular cycles and want a thorough hormonal workup, including FSH, estradiol, and thyroid panel interpretation
• You cannot afford $79 to $99/month for the subscription plus $550/month for fezolinetant without co-pay assistance
• You have PCOS, endometriosis, or a complex hormonal history that needs more than async messaging to manage safely
• You are pregnant, breastfeeding, or actively trying to conceive
• You prefer a clinician you can see and call by name, with clearly disclosed credentials

Women with PCOS entering perimenopause face a specific complexity: the hormonal shifts of the menopausal transition interact with insulin resistance and androgen excess in ways that require individualized management. A 2023 review in Fertility and Sterility noted that perimenopausal women with PCOS may have delayed menopause onset but face amplified metabolic risk in the transition. A platform that cannot accommodate that complexity is not the right primary care home for this group.

Practical Steps Before You Subscribe

1. Run the medication cost. Before you agree to any plan, call your pharmacy and ask for the cash price of fezolinetant 45 mg, then ask if your insurance covers it. Do this before paying the consultation fee.

2. Read the cancellation terms. Find the exact cancellation policy in the terms of service, not in the marketing copy. Screenshot it.

3. Verify your clinician's license. At your first appointment, ask for the clinician's full name and license number. Verify it at your state's medical board website.

4. Ask about alternatives. If fezolinetant is recommended immediately without a discussion of MHT, low-dose SSRI/SNRIs (paroxetine 7.5 mg, venlafaxine, or escitalopram), or gabapentin, ask why those options were skipped. Paroxetine 7.5 mg (Brisdelle) is the only non-hormonal drug FDA-approved specifically for VMS outside of fezolinetant, and it costs substantially less.

5. Check for patient assistance. If fezolinetant is appropriate for you, ask about the Astellas Veozah patient assistance program before paying full price.